At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,572 enrolled
Drug / intervention
Pneumococcal (vaccine)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
To Assess Safety, Reactogenicity and Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine, When Co-administered With DTPa-combined Vaccines and MenC or Hib-MenC Vaccines During the First 6 Months of Age.
In Brief
A Phase 3 clinical trial evaluating Pneumococcal (vaccine) for Infections, Streptococcal. Completed, enrolled 1,572 participants across 66 sites in 3 countries.
Detailed Summary
Three dose primary vaccination of healthy infants between 6 to 16 weeks of age at the time of the first vaccination against Streptococcus pneumonia, Neisseria meningitidis and Haemophilus influenzae type b.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfections, Streptococcal
CountriesGermany, Poland, Spain
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2006
First PostedJun 2006
Primary CompletionJul 2007
Study CompletionAug 2007
TodayJul 2026
First PostedJun 7, 2006
Enrollment StartJun 1, 2006
Primary CompletionJul 1, 2007
Study CompletionAug 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 20.1 years ago
Interventions
Pneumococcal (vaccine)biological